The University of Texas MD Anderson Cancer Center and Radiopharm Theranostics Ltd. have launched Radiopharm Ventures LLC, a joint venture (JV) that will develop radiopharmaceutical therapies for cancer. Radiopharm Theranostics owns 51% of shares in the new entity, while MD Anderson owns 49%.
The University of Texas MD Anderson Cancer Center and Radiopharm Theranostics Ltd. have launched Radiopharm Ventures LLC, a joint venture (JV) that will develop radiopharmaceutical therapies for cancer. Radiopharm Theranostics owns 51% of shares in the new entity, while MD Anderson owns 49%.
Seecure Taiwan Co. Ltd. has disclosed compounds reported to be useful for the treatment or diagnosis of cancer, autoimmune diseases and atherosclerosis.
From the beginning of the monkeypox outbreak in the U.S. in May, the federal government has bungled the response, according to both Democratic and Republican members of the Senate Health, Education, Labor and Pensions (HELP) Committee.
With a goal of manufacturing biotechnology in the U.S. that’s invented in the U.S., President Joe Biden signed an executive order Sept. 12 launching a National Biotechnology and Biomanufacturing Initiative that’s intended to strengthen the country’s bioeconomy, build stronger supply chains, and better utilize and secure biological data.
Analyzing RNA from blood platelets detected up to 18 different cancers, at early as well as late stages, with a specificity of 99% in asymptomatic controls. The specificity for symptomatic controls, including those who had inflammatory diseases, cardiovascular disease, or benign tumors, was 78%.
The Massachusetts Institute of Technology (MIT) has developed collagen mimetic peptides for PET imaging to detect idiopathic pulmonary fibrosis (IPF), with [68Ga]DOTA-CMP showing selective identification of fibrotic collagen in vivo.
An administrative law judge has decreed that the acquisition of Grail Inc., by Illumina Inc., would not represent a suppression of competition in the market for multicancer early detection (MCED) tests, clearing a way for an acquisition that was initially valued at more than $7 billion.
Researchers from Baylor College of Medicine and Texas Children's Hospital detailed the discovery of CPK-03-37, a novel fluorescent organic molecule for tumor imaging.
RSS
